Arrowhead Pharmaceuticals And Sarepta Therapeutics Enter Global License And Collaboration Deal For Genetic Disease Programs

Benzinga · 11/26 12:10
  • - Upon closing, Arrowhead will receive $825 million immediately, including an upfront payment and an equity investment at a 35% premium, and will receive an additional $250 million paid over five years
  • - Arrowhead has potential to receive an additional $300 million in near-term clinical trial enrollment-related milestone payments and is eligible for future potential milestone payments up to $10 billion and royalties on sales
  • - Sarepta to receive investigational treatments that leverage Arrowhead's leading Targeted RNAi Molecule platform